Cerenome

Q2 FY2026 EarningsQ2 FY26 missed consensus across all key profitability and revenue metrics. Revenue was $0.41M vs. $1.11M expected, while GAAP Net Loss of $9.01M was significantly wider than the anticipated $5.97M loss. Diluted EPS reached -$1.31 vs. consensus of -$0.88, driven by a 223% YoY surge in operating expenses as the company ramped up R&D for its REYOBIQ platform and expanded its CNSide diagnostic infrastructure. Management warned of substantial doubt regarding the company's ability to continue as a going concern, despite recent capital raises.